Building one of the largest datasets of gastric cancer peritoneal metastases in the world, we unravel new biology of organotropism, the important role of the tumor microenvironment and novel biomarkers. Just published in Gastroenterology! Joseph J Zhao gastrojournal.org/article/S0016-…

Jasmine Paolini’s 2024 Grand Slam season has come to an end. 🔹The woman with the most Grand Slam match wins this year (18) 🔹1st Italian woman to reach the Wimbledon final 🔹3rd Italian woman in history to reach the top 5 🔹1st Italian woman to reach a Grand Slam final in

First communication from the European GI network #Engic . Collaboration between Fédération Francophone de Cancérologie Digestive and #Gono on Engic02-PRODIGE 86 : LA or M+ small Bowel carcinoma. Design paper. Chiara Cremolini

🧮First-line chemotherapies in advanced pancreatic cancer The Lancet Oncology ✅Meta-analysis reaffirms NALIRIFOX /FOLFIRINOX as first-line regimens The Lancet OncoAlert Dr Joseph McCollom DO #cancer #oncology #MedX

Science-driven collaboration and not for the market - the Italian way 🇮🇹 of doing research is by passion and commitment for the community!

The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Phase 1b/2a Trial aacrjournals.org/clincancerres/…

Molecular Characterization and Clinical Relevance of MGMT-Silenced #PancreaticCancer CancerMedicine onlinelibrary.wiley.com/doi/10.1002/ca…

A successful trial by GONO Foundation , a brilliant effort of academic research. Congrats Filippo Pietrantonio and team!!!

Let's start with last session of grandangolo 2024 with a special focus on rare GU tumors Accademia Medicina Andrea Necchi Philippe spiess Istituto Tumori Meet-URO Monica Niger #genitourinarycancer

Meet the Author: Dr. Margherita Ambrosini (Margherita Ambrosini), an oncologist & PhD student from Hôpital européen Georges-Pompidou AP-HP Istituto Tumori, is 1st author of “Early treatment discontinuation in MMRd or MSI high metastastic colorectal cancer patients receiving immune checkpoint inhibitors,” in #JITC!

🔬 Biliary Tract Cancers Awareness Day 🟢💜💛 Biliary tract cancers—including cholangiocarcinoma, gallbladder cancer, and ampulla of Vater cancer—are rare but important to understand. Despite their impact, they remain understudied, underfunded, and often overlooked. 🌍 While

Istituto Tumori authors investigated feasibility and outcomes of a workflow for identification of germline carriers based on tumour sequencing results Monica Niger Federico Nichetti Elena Colombo marco stellato #OpenAccess 🔗journals.sagepub.com/doi/full/10.11… #MolecularTumourBoard #GynCSM #bcsm

In this review we go through the key aspects that characterize MSI-H/dMMR cancers, in light of recent diagnostic advances and the successes of immune checkpoint inhibitors in both advanced and early stage disease. Have a look! nature.com/articles/s4157…

Have a look at my review seeking to help clinicians gain familiarity with the correct reading and interpretation of #QoL results in cancer clinical trials, just published in NEJM Evidence OncoDaily OncoAlert evidence.nejm.org/doi/full/10.10…

T-DXd vs RAM + paclitaxel in 2nd line HER2+ EC/GEJC #ASCO25 🔎DESTINY-Gastric04 phs-III 👉ORR 44 vs 29% 👉mPFS 6.7 vs 5.6 mo, HR 0.74 👉mOS 14.7 vs 11.4 mo, HR 0.7 👉TEAE ≥3 74% vs 68% 🧐 Positive study, support T-DXd in earlier setting ESMO - Eur. Oncology

Neoadjuvant Gem/Cis vs radical liver resection followed by adjuvant therapy in BTC #ASCO25 🔎 phase III AIO/CALGP/ACO-GAIN-Trial. 👉RO 83 vs 40% 👉mEFS 14 vs 4 mo 👉mOS 27 vs 14 mo 🧐 Strong signal, but unfortunately stopped premature. 🧐 Supports neaadjuvant strategies in BTC

Finally published: Real-World outcomes of Istituto Tumori Molecular Tumor Board treatment recommendations JCO Precision Oncology Giancarlo Pruneri ascopubs.org/doi/10.1200/PO…

🔥Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer🔥 👉great news, another 🇪🇺 approval in BTC 🧐Don't forget IHC Her2 testing in BTC! ESMO - Eur. Oncology EASL Education ILCA

Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapy 👉 karger.com/ocl/article-ab… 📌 In this multicenter study: •Antibiotics within 15 days before treatment → worse OS & PFS •More studies needed to clarify impact

A great collaboration showing real-life results of ivosidenib! Thanks to andrea casadei gardini and all the co-authors for the effort! Cholangiocarcinoma Foundation